Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 6/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE6D | O43924 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124865 | 0.81 | KMT2A (0.49) | KDM4EKMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL9685516 | 0.79 | KDM4E (0.77) | KDM4EKMT2ASMN1; SMN2LMNARAD52 | |
| Hydrochloric Acid SCHEMBL9684702 | 0.78 | KDM4E (0.75) | KDM4EKMT2ASMN1; SMN2LMNARAD52 | |
| SCHEMBL2833179 | 0.76 | PKM (0.50) | KDM4EKMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL12135957 | 0.73 | KMT2A (0.47) | KDM4EKMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL14671469 | 0.70 | KMT2A (0.47) | KDM4EKMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL20521940 | 0.70 | KMT2A (0.44) | KMT2ASMN1; SMN2LMNAPOLBRAD52 | |
| SCHEMBL2838064 | 0.69 | KDM4E (0.55) | KDM4EKMT2ALMNAPOLBMEN1 | |
| SCHEMBL2125303 | 0.69 | CYP3A4 (0.49) | KDM4EKMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL30615186 | 0.68 | KMT2A (0.42) | KDM4EKMT2ASMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-9694006-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | disclosed |
| US-8207187-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| CN-101594866-A | The preparation of local usefulness | HELPERBY THERAPEUTICS LTD (GB) | 2009-12-02 | — | — | CN | disclosed |
| EP-2086542-A1 | TOPICAL FORMULATIONS | Helperby Therapeutics Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| CN-101351203-A | Application of pyrroloquinoline compound in killing clinically latent microorganisms | HELPERBY THERAPEUTICS LTD (GB) | 2009-01-21 | — | — | CN | disclosed |
| EP-1945211-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008056151-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007054693-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | KDM4E 1494/4885KMT2A 2403/4885SMN1; SMN2 4384/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | KDM4E 1494/4885KMT2A 2403/4885SMN1; SMN2 4384/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | KDM4E 1494/4885KMT2A 2403/4885SMN1; SMN2 4384/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | KDM4E 2890/4885KMT2A 4302/4885SMN1; SMN2 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.